Canada’s Amendment to Patented Drug Price Regulation

This Viewpoint reviews proposed changes to regulations governing Canada’s Patented Medicine Process Review Board, a group mandated by Canada’s government to ensure manufacturers do not charge excessive drug prices, including use of cost-utility analyses to define excessive pricing, revision of reference country comparisons, and reducing regulatory burdens for generic drugs.